
Results
224
Mid-Large Cap Stocks
224 companies
Bristol-Myers Squibb
Market Cap: US$113.1b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$57.52
7D
6.5%
1Y
24.1%
Johnson & Johnson
Market Cap: US$589.5b
Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
JNJ
US$254.66
7D
11.5%
1Y
67.1%
Zoetis
Market Cap: US$32.6b
Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
ZTS
US$76.09
7D
-3.3%
1Y
-51.3%
Amgen
Market Cap: US$190.4b
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
AMGN
US$358.33
7D
6.1%
1Y
29.3%
Gilead Sciences
Market Cap: US$153.8b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$127.88
7D
3.3%
1Y
15.6%
AbbVie
Market Cap: US$429.6b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$253.35
7D
17.0%
1Y
39.0%
Merck
Market Cap: US$309.8b
Operates as a healthcare company worldwide.
MRK
US$128.66
7D
13.0%
1Y
62.7%
Phibro Animal Health
Market Cap: US$1.3b
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
PAHC
US$31.69
7D
-0.5%
1Y
23.5%
Agilent Technologies
Market Cap: US$38.3b
Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
A
US$136.01
7D
7.0%
1Y
14.1%
Pfizer
Market Cap: US$134.9b
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
PFE
US$24.29
7D
-3.6%
1Y
0.4%
Perrigo
Market Cap: US$1.3b
Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
PRGO
US$9.95
7D
-2.9%
1Y
-62.5%
Danaher
Market Cap: US$136.7b
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
DHR
US$196.19
7D
10.7%
1Y
-1.3%
Viatris
Market Cap: US$18.7b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$16.33
7D
6.2%
1Y
81.2%
Qiagen
Market Cap: US$8.1b
Provides sample to insight solutions that transform biological samples into molecular insights worldwide.
QGEN
US$39.41
7D
6.7%
1Y
-21.6%
Royalty Pharma
Market Cap: US$31.5b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$56.23
7D
6.2%
1Y
56.8%
AnaptysBio
Market Cap: US$1.7b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$63.15
7D
9.8%
1Y
181.0%
Hisamitsu Pharmaceutical
Market Cap: US$8.2b
Manufactures and sells pharmaceuticals in Japan.
HTSU.Y
US$4.55
7D
0%
1Y
n/a
Arcus Biosciences
Market Cap: US$3.8b
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
RCUS
US$31.00
7D
27.5%
1Y
289.9%
Corcept Therapeutics
Market Cap: US$9.1b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$87.32
7D
9.3%
1Y
19.3%
GH Research
Market Cap: US$1.7b
Together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
GHRS
US$28.22
7D
26.9%
1Y
126.8%
Kodiak Sciences
Market Cap: US$2.1b
A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
KOD
US$35.94
7D
-0.6%
1Y
871.4%
Nurix Therapeutics
Market Cap: US$2.3b
A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
NRIX
US$22.90
7D
30.5%
1Y
96.7%
MeiraGTx Holdings
Market Cap: US$1.1b
A clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
MGTX
US$12.11
7D
7.0%
1Y
83.2%
UroGen Pharma
Market Cap: US$1.7b
A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$34.54
7D
2.9%
1Y
156.0%
Capricor Therapeutics
Market Cap: US$1.8b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$26.44
7D
-6.8%
1Y
137.1%
Revolution Medicines
Market Cap: US$37.9b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$182.08
7D
11.7%
1Y
393.3%
Intellia Therapeutics
Market Cap: US$2.2b
Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
NTLA
US$16.68
7D
6.4%
1Y
74.5%
TG Therapeutics
Market Cap: US$7.6b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$55.83
7D
4.9%
1Y
52.0%
Biogen
Market Cap: US$29.8b
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
BIIB
US$216.03
7D
9.9%
1Y
71.3%
Alnylam Pharmaceuticals
Market Cap: US$39.1b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$291.37
7D
4.8%
1Y
-9.7%
BioLife Solutions
Market Cap: US$1.3b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$28.67
7D
10.1%
1Y
33.4%
Dianthus Therapeutics
Market Cap: US$5.0b
A clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
DNTH
US$95.28
7D
15.5%
1Y
440.4%
BioNTech
Market Cap: US$22.8b
Engages in the development and commercialization of immunotherapies in Germany.
BNTX
US$91.22
7D
0.4%
1Y
-14.5%
Vaxcyte
Market Cap: US$7.8b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$56.52
7D
9.9%
1Y
73.5%
Axsome Therapeutics
Market Cap: US$12.2b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$241.67
7D
-3.5%
1Y
133.8%
Exelixis
Market Cap: US$13.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$54.79
7D
5.5%
1Y
25.5%